Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy

Clinica Chimica Acta

Volumn 223, Issue 1-2, 1993, Pages 43-52

  Dnistrian, Ann M ^a   Schwartz, Morton K ^a   Greenberg, Ernest J ^a   Smith, Caroi A ^a   Schwartz, Delia C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Cardiovascular risk; Serum cholesterol; Serum lipoproteins; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHOLESTEROL; FEMALE; HUMAN; LIPOPROTEINS; LIPOPROTEINS, HDL CHOLESTEROL; LIPOPROTEINS, LDL CHOLESTEROL; MENOPAUSE; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN;

EID: 0027769350     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-8981(93)90061-8     Document Type: Article

References (33)

1. Chemosuppression of breast cancer with tamoxifen laboratory evidence and 3 future clinical investigations
2. Long-term adjuvant tamoxifen therapy for breast cancer
3. Long-term adjuvant tamoxifen therapy for breast cancer the prelude to prevention
4. The strategic use of antiestrogens to control the development and growth of breast cancer
5. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study
6. Evaluation of paradigms for the management of breast cancer a personal perspective
7. Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen
8. Adjuvant tamoxifen in primary breast cancer influence on plasma lipids and antithrombin III levels
9. Serum lipoproteins and cardiovascular risk
10. A pilot trials to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer
11. Effect of tamoxifen treatment on plasma lipids and lipoprotein lipid composition
12. Tamoxifen use oestrogen binding and serum lipids in postmenopausal women with breast cancer
13. Serum cholesterol reduction with tamoxifen
14. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
15. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative breast cancer
16. Effect of tamoxifen therapy on serum cholesterol and lipoprotein levels in breast cancer patients
17. 3 in human plasma
18. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge
19. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients
20. Chemohormonal therapy and endocrine function in breast cancer patients
21. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer
22. Estrogen replacement and coronary heart disease
23. Menopause and risk factors for coronary heart disease
24. High density lipoprotein as a protective factor against coronary artery disease the Framingham study
25. HDL cholesterol and the other lipids in coronary heart disease the Cooperative Lipoprotein Phenotyping Study
26. The epidemiology of plasma high density lipoprotein cholesterol levels
27. Differential effect of tamoxifen on cholesterol and serum lipoprotein profiles in breast cancer patients
28. Tamoxifen as a potential preventive agent in healthy postmenopausal women
29. Potential role of tamoxifen in prevention of breast cancer
30. Tamoxifen for the prevention of breast cancer
31. New perspective on cancer of the contralateral breast a marker for assessing tamoxifen as a preventive agent
32. Contralateral primary tumors in breast cancer patients in a random trial of adjuvant tamoxifen therapy
33. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as a single agent